TMCnet News
Bioprocess Technology Market to Reach USD 134.06 Billion by 2035 - Credence ResearchLONDON, Oct. 15, 2026 /PRNewswire/ -- The "Bioprocess Technology Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2035" report has been added to the Credence Research Inc. market intelligence offering.
The global bioprocess technology market was valued at USD 55.63 billion in 2025 and is estimated at USD 60.75 billion in 2026. Revenue is projected to reach USD 134.06 billion by 2035, representing a compound annual growth rate (CAGR) of 9.19% over the 2025–2035 market-value interval. North America held the largest regional share at 40.0% in 2025, while Asia Pacific is expected to record the fastest growth at 10.38% annually. These revenue forecasts and market shares are Credence Research estimates. Key Takeaways
Scope & Segmentation - Bioprocess Technology Market Production equipment, consumables and process technology used to culture cells and purify biologic drug substances, including bioreactors, media, filters, chromatography systems, resins, membranes and analytical instruments. Finished biologic sales, fill-finish equipment and contract manufacturing service revenue are excluded to avoid conflating tools with their end products.
Download sample and detailed segmentation - https://www.credenceresearch.com/report/bioprocess-technology-market Why This Report Matters
Market Overview Bioprocess equipment and consumables are critical inputs for making antibodies, vaccines, recombinant proteins and advanced therapies. Unlike the revenue of finished biological medicines, this market measures instruments and materials purchased to manufacture them. Plant builders invest in bioreactors and purification systems when new capacity comes online, while validated commercial facilities buy media, bags, membranes, resins and reagents repeatedly. Product mix is therefore unusually sensitive to capacity utilization and whether a manufacturer operates stainless steel or single-use systems. Market Insights
Key Attributes
Market Segmentation By product Instruments; Consumables and accessories By process type Upstream processing; Downstream processing By technology Batch; Fed-batch; Continuous processing By application Monoclonal antibodies; Recombinant proteins; Cell and gene therapy products; Antibiotics; Others Market Drivers Growing commercial biologic capacity Biopharmaceutical companies and contract development and manufacturing organizations are expanding capacity for antibody and cell therapy pipelines. The commissioning of additional sites requires upfront investment in bioreactors, filtration and process monitoring, while each subsequent batch consumes materials that deliver recurring revenue for suppliers. Shift toward intensification and single-use workflows Single-use bioreactors shorten turnaround between products and reduce cleaning validation requirements. Intensified perfusion and connected purification can raise output per unit of capacity, but changes to commercial processes require regulatory comparability evidence. Manufacturers often adopt these tools most readily in new plants rather than retrofit fully validated facilities. Market Trends and Opportunities Suppliers increasingly offer complete upstream and downstream product ranges. In September 2025, Thermo Fisher completed its approximately USD 4 billion acquisition of Solventum's filtration and purification business, adding membranes and related technologies. Process analytical technology, including inline sensors and automated control, may reduce deviation risk and support more efficient batch release. Regulatory incentives can help, although equipment qualification and implementation remain facility-specific. Regional Analysis Credence Research estimates the following 2025 revenue shares. All five regional figures are proprietary research-model allocations rather than independently audited sales totals. North America | 40.0% share in 2025 Established biologics capacity and broad pipelines support recurring demand for resins, media and filters. U.S. manufacturers are also evaluating advanced manufacturing designation and process intensification. Europe | 29.0% share in 2025 Biologics manufacturing hubs in Switzerland, Germany, Ireland and Denmark support equipment replacement and specialized upstream and downstream consumables. Asia Pacific | 23.0% share in 2025 New CDMO plants and biosimilar capacity in South Korea, China, India and Singapore are driving 10.38% annual modeled growth. Latin America | 4.5% share in 2025 Vaccine, insulin and biosimilar localization programs expand demand for fermentation, filtration and purification tools, especially in Brazil and Mexico. Middle East and Africa | 3.5% share in 2025 Local biomanufacturing initiatives create opportunities for modular systems, while workforce and validation constraints limit implementation scale. Market Challenges A change in resins, membrane materials or equipment may require new process validation and regulatory submissions. For established products, switching can be uneconomical despite the potential for productivity gains. Capital-intensive instrument orders can fluctuate with biotechnology funding and construction schedules. Specialized operators and quality staff remain scarce, while single-use plastic waste and supply dependence create operational constraints. Future Outlook Bioprocess spending is expected to grow fastest where new CDMO capacity meets expanding portfolios of complex biologics. Consumables should preserve repeat sales even if capital project timing varies. The strongest technology providers will combine dependable supply, process documentation, training, high-value purification tools and automation support. Competitive Landscape Competition among full-line suppliers centers on the breadth of validated components and integrated production workflows. Thermo Fisher, Danaher, Sartorius and Merck KGaA supply combinations of cell culture, filtration and purification products. Eppendorf, Bio-Rad, Agilent and specialized equipment firms compete in process development, analytics and particular hardware categories. Lonza and Roche are major manufacturing operators and equipment customers, rather than primarily direct competitors as process-tool vendors. Key Players
Recent Industry Developments
Report Coverage
Read the complete report and request a customized study: https://www.credenceresearch.com/report/bioprocess-technology-market Related Reports
About Us Credence Research Inc. is a global market intelligence and consulting firm founded in 2015. The company provides quantitative industry research, competitive analysis and strategic advisory services to organizations assessing market opportunities and investment decisions. Its reports combine primary and secondary research to evaluate market size, segmentation, growth drivers, emerging technologies and regional commercial conditions. Credence Research serves business leaders, investors, governments, nonprofits and other stakeholders across industries, with research deliverables designed to inform product planning, market entry and competitive positioning. Contact Us Credence Research Inc. Website: www.credenceresearch.com
SOURCE Credence Research Inc. 
|
View original content to download multimedia: